Crucell, DSM Biologics N.V., GlaxoSmithKline deal

GSK received a license to the PER.C6 cell line from CRXL and CRXL's contract manufacturing partner, DSM. GSK will use the cell line for research and preclinical development of its monoclonal antibodie...